País: Austrália
Língua: inglês
Origem: Department of Health (Therapeutic Goods Administration)
oxaliplatin, Quantity: 50 mg
Medis Pharma Pty Ltd
Oxaliplatin
Injection, powder for
Excipient Ingredients: mannitol
Intravenous
1 vial
(S4) Prescription Only Medicine
In combination with fluorouracil and folinic acid: adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour; and treatment of advanced colorectal cancer.
Visual Identification: White or almost white freeze-dried powder in a vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2007-09-07
CONSUMER MEDICINE INFORM AT ION Oxaliplan CMI artwork.indd 1 2/18/2008 2:17:02 PM Oxaliplan CMI artwork.indd 2 2/18/2008 2:17:03 PM Leia o documento completo
_Product Information:Oxaliplan (50mg and 100mg) _ _v3 September 2010 clean copy _ 1 PRODUCT INFORMATION OXALIPLAN TM NAME OF THE MEDICINE Oxaliplan contains 50 or 100 mg of Oxaliplatin per vial. The formulation also contains mannitol. The full chemical name of Oxaliplatin is (SP-4-2)-[(1R,2R )-Cyclohexane-1,2-diamine-κN, κN1] [ethanedioato(2-)- κO1,κO2]platinum. The Chemical Abstracts Name is: [(1R,2R)-1,2-cyclohexanediamine-N,N’][oxalate(2-)O,O’]platine(II) DESCRIPTION Molecular formula: C 8 H 14 N 2 O 4 Pt Molecular Weight: 397.3 CAS Number: 61825-94-3 Chemical Structure: Oxaliplatin is a white to off-white crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and practically insoluble in ethanol. PHARMACOLOGY Pharmacodynamics: Oxaliplatin is an antineoplastic drug belonging to a class of platinum based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and an oxalate group. Oxaliplatin is a single enantiomer, the cis-[oxalato (trans-1-1,2- DACH) platinum]. Oxaliplatin exhibits a wide spectrum of both in vitro cytotoxicity and in vivo antitumour activity in a variety of tumour model systems, including human colorectal cancer models. Oxaliplatin also demonstrates in vitro and in vivo activity in various cisplatin resistant models. A synergistic cytotoxic action has been observed in combination with fluorouracil both in vitro and in vivo. Studies on the mechanism of action of Oxaliplatin, although not completely elucidated, show that the aqua derivatives resulting from the biotransformation of Oxaliplatin interact with DNA to form both inter and intra strand cross links, resulting in the disruption of DNA synthesis leading to cytotoxic and antitumour effects. Pharmacokinetics: The pharmacokinetics of individual active compounds have not been determined. The pharmacokinetics of ultrafiltrable platinum, representing a mixture of all unbound, active and inactive platinum species, following a two hour infusion of Oxaliplatin at 130 mg/m2 every Leia o documento completo